On Pharma Trends and Big Company Innovation

Episode Summary

Executive Summary: Novartis CEO Voss (Novartis CEO) argues that pharma must become far more disciplined, selective, and engineering-driven as science advances. He describes a shift toward advanced modalities—cell/gene therapy, RNA, digital therapeutics, and data science—while emphasizing that attrition remains stubbornly high, reimbursement must be considered early, and technology should reduce clinical trial complexity and cost.

Main Topics: Portfolio Discipline and Strategic Focus: Novartis has deliberately exited or spun off businesses where it cannot be a long-term leader, while concentrating capital on medicines powered by advanced therapy platforms and data science. R&D Reality: High Attrition, Rising Complexity: Despite scientific advances, only a small fraction of medicines succeed in humans. The company stresses discipline, patience, and stopping weak projects early to avoid crowding out better opportunities. From Molecules to Cell/Gene Engineering: The discussion traces the evolution of therapeutics from small molecules and biologics to RNA, cell therapy, gene therapy, and regenerative medicine, with a growing emphasis on modular platforms. Reimbursement and Market Access as Early Design Constraints: Market access and payer value are now considered during early development, not just at launch, because therapeutic value must be transformative to justify adoption and pricing. AI, Data Science, and Clinical Trial Modernization: Novartis sees the biggest near-term AI wins in image analysis, operational forecasting, and financial prediction, while acknowledging that unstructured clinical data remains hard to use. Build vs. Buy, Acquisitions, and Integration: The company selectively acquires external innovation when others have advanced further, then preserves new platforms as independent units to avoid crushing them inside a large organization. Culture, Talent, and Operating Like a Modern Knowledge Company: Novartis is shifting from an industrial model to an empowered, rapid-iteration culture—'inspired, curious, and unbossed'—to fit knowledge work and biotech uncertainty.

Key Arguments: Novartis must focus on areas where it can sustain depth and leadership; subscale therapeutic areas should be exited rather than maintained out of inertia. Scientific progress has accelerated, but human biology is still poorly understood, so industry-wide clinical success rates have not materially improved. The best projects are those that can redefine standard of care, not merely offer incremental improvement. Clinical trial costs keep rising because complexity, regulation, and measurement requirements keep increasing; technology could cut costs materially if deployed at scale. Reimbursement is a proxy for real value; founders should work backward from payer willingness to pay, not just from FDA approval. Digital therapeutics can be real medicines when they have clinical evidence and FDA labeling, though their best fit is likely in behavioral or behavior-influenced conditions. Cell and gene therapy are becoming platform businesses: once manufacturing and delivery are solved, the same infrastructure can support multiple diseases. AI is most effective today where data are structured or image-based; the biggest bottleneck is data quality, harmonization, and linkage. Randomized, blinded trials remain essential; real-world evidence and sensors are helpful complements but not replacements for controlled studies. Large pharma should partner with startups and universities to access data science talent and innovation, while lowering the barrier for entrepreneurs to collaborate.

Data Points: Novartis medicine volume: 70 billion doses per year - Scale of Novartis medicines across therapeutic areas Patients reached annually: About 1 billion patients - Global access reached through Novartis, especially via generics/Sandoz Industry human success rate: About 5% - Roughly 1 out of 20 medicines works once tested in humans Novartis internal success rate: 8% to 10% - Company-level average mentioned as better than industry average Clinical trial cost reduction potential: 20% - Estimated savings if technology were deployed at scale 2018 deal activity: Around $50 billion - Portfolio reshaping through acquisitions/exits to change company direction Last year’s acquisitions in advanced therapies: $15 billion - Investments to build infrastructure in new modalities, especially gene/cell therapy R&D headcount: 17,000 people - Size of Novartis R&D organization Annual R&D spend: $9 billion plus - Company investment in research and development Company workforce: 120,000 people in 150 countries - Scale of Novartis as a global enterprise Clinical trials conducted annually: 400 to 500 - Volume used to train operations-focused AI systems Clinical-trial history used for AI: 10 years - Time span of historical operational data used for models Clinical imaging data: 2 million patients - Clinical trial imaging archive used for ML applications Hybrid workforce: 50% millennials - Workforce composition tied to culture shift and digital-native expectations FDA molecular innovation count: About 1,500 new molecular entities ever found - Historical scale of drug discovery since the FDA's creation

Pivotal Quotes: "“We say to ourselves, it has to replace the standard of care.”" — Voss: Describing the new bar for advancing internal R&D projects "“Only one out of 20 works.”" — Voss: Explaining the persistent ~5% success rate once medicines reach humans "“Inspired, curious, and unbossed.”" — Voss: Novartis’s stated culture shift for a knowledge-worker, innovation-driven company

Implications: Pharma’s future will be more platform-based, data-driven, and selective. Winners will combine strong science with manufacturing, access strategy, and engineering discipline; startups that align with these needs can become valuable partners or acquisition targets.